CompletedNCT04567303
Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration
PHASE1 · PHASE2 · 177 planned enrolment
- Countries listed
- 2
- Registry update
- September 14, 2026
Registry Intervention View
ranibizumab
Trial registrations containing the exact intervention label ranibizumab.
Exact registry label · Not reported
96 linked registrations
No aliases or equivalent products have been inferred.
Topics connected by trial metadata
41 linked registrations report posted results
This is a registry availability fact, not a safety result, comparison, or conclusion.
Understand the safety boundary →Registered trials
Not Yet RecruitingNCT07816289
Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-05)
PHASE3 · 400 planned enrolment
- Countries listed
- 0
- Registry update
- September 11, 2026
Enrolling By InvitationNCT05210803
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD
PHASE2 · 116 planned enrolment
- Countries listed
- 1
- Registry update
- August 5, 2026
CompletedNCT03834753
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
PHASE3 · 228 planned enrolment
- Countries listed
- 1
- Registry update
- August 3, 2026
Active Not RecruitingNCT04657289
A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)
PHASE3 · 451 planned enrolment
- Countries listed
- 16
- Registry update
- July 31, 2026
CompletedNCT06190093
A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
PHASE3 · 400 planned enrolment
- Countries listed
- 1
- Registry update
- July 23, 2026
Active Not RecruitingNCT04514653
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)
PHASE2 · 146 planned enrolment
- Countries listed
- 1
- Registry update
- February 27, 2026
CompletedNCT03844074
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
PHASE3 · 61 planned enrolment
- Countries listed
- 1
- Registry update
- March 19, 2025
TerminatedNCT01944839
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
PHASE3 · 619 planned enrolment
- Countries listed
- 13
- Registry update
- October 30, 2024
TerminatedNCT01940900
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
PHASE3 · 627 planned enrolment
- Countries listed
- 11
- Registry update
- October 30, 2024
TerminatedNCT02387957
A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)
PHASE2 · 63 planned enrolment
- Countries listed
- 1
- Registry update
- October 30, 2024
CompletedNCT04662944
A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections
Phase not reported · 494 planned enrolment
- Countries listed
- 5
- Registry update
- June 18, 2024
WithdrawnNCT05126966
A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration
PHASE3 · 0 planned enrolment
- Countries listed
- 7
- Registry update
- January 18, 2024
UnknownNCT05480293
This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD
PHASE3 · 446 planned enrolment
- Countries listed
- 1
- Registry update
- February 16, 2023
CompletedNCT03725501
Evaluation of the Safety and Efficacy of ALS-L1023 Administered in Combination With Ranibizumab in Patients With Wet-AMD
PHASE2 · 126 planned enrolment
- Countries listed
- 1
- Registry update
- August 11, 2022
CompletedNCT05110209
Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)
Phase not reported · 331,541 planned enrolment
- Countries listed
- 1
- Registry update
- December 21, 2021
CompletedNCT05146687
Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)
Phase not reported · 369,600 planned enrolment
- Countries listed
- 1
- Registry update
- December 16, 2021
CompletedNCT02611778
Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration
PHASE3 · 712 planned enrolment
- Countries listed
- 12
- Registry update
- September 30, 2021
CompletedNCT02510794
Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration
PHASE2 · 225 planned enrolment
- Countries listed
- 1
- Registry update
- May 6, 2021
CompletedNCT03345082
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
PHASE2 · 366 planned enrolment
- Countries listed
- 10
- Registry update
- January 12, 2021
CompletedNCT02707575
Cytokeratin 8 Level in Age-related Macular Degeneration
Phase not reported · 58 planned enrolment
- Countries listed
- 1
- Registry update
- December 9, 2020
CompletedNCT02484690
A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
PHASE2 · 273 planned enrolment
- Countries listed
- 1
- Registry update
- November 12, 2020
CompletedNCT00473642
Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration
PHASE4 · 31 planned enrolment
- Countries listed
- 1
- Registry update
- November 6, 2020
CompletedNCT03423823
Ziv-aflibercept Efficacy in Better Regulating AMD
PHASE2 · 62 planned enrolment
- Countries listed
- 1
- Registry update
- October 6, 2020
CompletedNCT02358889
Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
PHASE2 · 88 planned enrolment
- Countries listed
- 1
- Registry update
- September 24, 2020
CompletedNCT02462486
Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration
PHASE3 · 949 planned enrolment
- Countries listed
- 16
- Registry update
- July 30, 2020
CompletedNCT02462928
A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration
PHASE3 · 939 planned enrolment
- Countries listed
- 17
- Registry update
- July 28, 2020
CompletedNCT01972789
Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre)
PHASE4 · 349 planned enrolment
- Countries listed
- 1
- Registry update
- October 23, 2019
UnknownNCT02976194
Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy
PHASE4 · 28 planned enrolment
- Countries listed
- 1
- Registry update
- October 10, 2019
CompletedNCT01775124
Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)
PHASE4 · 332 planned enrolment
- Countries listed
- 1
- Registry update
- September 4, 2019
TerminatedNCT01402544
Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab
PHASE2 · PHASE3 · 20 planned enrolment
- Countries listed
- 1
- Registry update
- August 28, 2019
CompletedNCT01464723
Study EvAluating Genotypes While Using Lucentis 2
PHASE4 · 66 planned enrolment
- Countries listed
- 1
- Registry update
- August 14, 2019
CompletedNCT01846273
Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT)
PHASE4 · 321 planned enrolment
- Countries listed
- 7
- Registry update
- June 7, 2019
UnknownNCT03944070
Management of Patients With Neovascular Age-related Macular Degeneration Undergoing Cataract Surgery
Phase not reported · 16 planned enrolment
- Countries listed
- 1
- Registry update
- May 9, 2019
CompletedNCT00511706
Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)
PHASE2 · 243 planned enrolment
- Countries listed
- 9
- Registry update
- April 25, 2019
CompletedNCT01397409
Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)
PHASE2 · 271 planned enrolment
- Countries listed
- 8
- Registry update
- April 16, 2019
CompletedNCT01958918
Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD
PHASE4 · 712 planned enrolment
- Countries listed
- 10
- Registry update
- March 21, 2019
CompletedNCT02161575
Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD
PHASE4 · 103 planned enrolment
- Countries listed
- 2
- Registry update
- February 15, 2019
CompletedNCT01972763
Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept.
PHASE1 · PHASE2 · 12 planned enrolment
- Countries listed
- 1
- Registry update
- February 5, 2019
CompletedNCT02530918
Study of DS-7080a for the Treatment of Macular Degeneration
PHASE1 · 56 planned enrolment
- Countries listed
- 1
- Registry update
- May 9, 2018
CompletedNCT02843490
Functional and Structural Outcomes in Neovascular Age-related Macular Degeneration
PHASE4 · 71 planned enrolment
- Countries listed
- 1
- Registry update
- December 2, 2017
CompletedNCT02577107
Head to Head Study of Anti-VEGF Treatment.
PHASE4 · 12 planned enrolment
- Countries listed
- 1
- Registry update
- November 30, 2017
CompletedNCT02291887
Genetic Analysis of Patients Responsive to Ranibizumab But Resistant to Aflibercept
Phase not reported · 13 planned enrolment
- Countries listed
- 1
- Registry update
- November 17, 2017
CompletedNCT00593450
Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial
PHASE3 · 1,208 planned enrolment
- Countries listed
- 1
- Registry update
- August 21, 2017
CompletedNCT01780935
Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration
PHASE3 · 671 planned enrolment
- Countries listed
- 24
- Registry update
- August 14, 2017
UnknownNCT02727881
Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD
PHASE3 · 230 planned enrolment
- Countries listed
- 1
- Registry update
- April 27, 2017
WithdrawnNCT02511613
Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration
PHASE2 · 0 planned enrolment
- Countries listed
- 1
- Registry update
- April 27, 2017
CompletedNCT02181504
A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration
PHASE2 · 25 planned enrolment
- Countries listed
- 1
- Registry update
- April 25, 2017
WithdrawnNCT02634970
CANadian Study in Patients With Wet AMD, Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to RanIbizumab
PHASE4 · 0 planned enrolment
- Countries listed
- 0
- Registry update
- February 15, 2017
TerminatedNCT01025232
A Study of Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial)
PHASE1 · PHASE2 · 88 planned enrolment
- Countries listed
- 1
- Registry update
- January 2, 2017
CompletedNCT00470678
EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
PHASE3 · 95 planned enrolment
- Countries listed
- 2
- Registry update
- November 18, 2016
UnknownNCT02810808
Safety and Efficacy of Two Regimens of Ranibizumab 0.5 mg in Chinese Patients With Neovascular AMD
PHASE4 · 115 planned enrolment
- Countries listed
- 1
- Registry update
- November 4, 2016
UnknownNCT02864472
Comparison of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV With Initial Loading Dose
PHASE4 · 40 planned enrolment
- Countries listed
- 0
- Registry update
- August 12, 2016
CompletedNCT02118831
Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF
PHASE1 · PHASE2 · 56 planned enrolment
- Countries listed
- 0
- Registry update
- May 19, 2016
CompletedNCT02181517
A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration
PHASE2 · 25 planned enrolment
- Countries listed
- 1
- Registry update
- May 17, 2016
CompletedNCT01810042
Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab
PHASE4 · 49 planned enrolment
- Countries listed
- 1
- Registry update
- May 4, 2016
CompletedNCT00967213
Combination of Ranibizumab and Verteporfin Therapy in Neovascular Age-related Macular Degeneration
PHASE3 · 10 planned enrolment
- Countries listed
- 1
- Registry update
- April 22, 2016
WithdrawnNCT02036723
Safety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macular Degeneration
PHASE3 · 0 planned enrolment
- Countries listed
- 2
- Registry update
- March 31, 2016
TerminatedNCT01189019
HiPED - High Dose Lucentis for Persistent Pigment Epithelial Detachments in Age-related Macular Degeneration
PHASE2 · 40 planned enrolment
- Countries listed
- 1
- Registry update
- March 29, 2016
CompletedNCT01849692
ESBA1008 Microvolume Study
PHASE2 · 107 planned enrolment
- Countries listed
- 0
- Registry update
- March 24, 2016
CompletedNCT01363570
Evaluation of Wet Age-Related Macular Degeneration (AMD) Genetic Profile Interactions With Ranibizumab Treatment Outcomes
Phase not reported · 70 planned enrolment
- Countries listed
- 1
- Registry update
- March 17, 2016
CompletedNCT00504959
Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration
PHASE4 · 234 planned enrolment
- Countries listed
- 10
- Registry update
- March 4, 2016
CompletedNCT00727753
VEGF-antagonism and Endothelial Function in Age-related Macular Degeneration (AMD)
Phase not reported · 54 planned enrolment
- Countries listed
- 1
- Registry update
- May 28, 2015
CompletedNCT00791427
ERG/EOG Study in AMD Patients Treated With Ranibizumab
Phase not reported · 10 planned enrolment
- Countries listed
- 1
- Registry update
- May 8, 2015
CompletedNCT01500915
FUSION Regimen: Combined Pro re Nata and Fixed Regimen Ranibizumab in Exudative Age-related Macular Degeneration
PHASE4 · 17 planned enrolment
- Countries listed
- 1
- Registry update
- March 24, 2015
UnknownNCT02372916
Geographic Atrophy and Intravitreal Ranibizumab Injections
Phase not reported · 90 planned enrolment
- Countries listed
- 1
- Registry update
- February 26, 2015
CompletedNCT01127360
LUCAS (Lucentis Compared to Avastin Study)
PHASE4 · 420 planned enrolment
- Countries listed
- 1
- Registry update
- January 16, 2015
UnknownNCT02328209
Evaluation of the Simplified Treat And Extend Regimen Using Ranibizumab in Exudative Age Related Macular Degeneration
Phase not reported · 50 planned enrolment
- Countries listed
- 1
- Registry update
- December 31, 2014
CompletedNCT00637377
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)
PHASE3 · 1,240 planned enrolment
- Countries listed
- 26
- Registry update
- December 12, 2014
CompletedNCT01933152
Study to Assess the EffectiVeness of exIsting Anti-vascular Endothelial groWth Factor (Anti-VEGF) Treatment Regimens in Patients With Wet Age-related Macular Degeneration
Phase not reported · 137 planned enrolment
- Countries listed
- 1
- Registry update
- October 1, 2014
CompletedNCT02060604
Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration
PHASE4 · 60 planned enrolment
- Countries listed
- 1
- Registry update
- February 12, 2014
CompletedNCT01447043
Study to Assess the Effectiveness of Existing Anti vascUlar Endothelial Growth Factor (Anti VEGF) in Patients With Wet Age-related Macular Degeneration (wAMD) (AURA)
Phase not reported · 2,609 planned enrolment
- Countries listed
- 10
- Registry update
- January 27, 2014
CompletedNCT01157065
Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration
PHASE2 · 99 planned enrolment
- Countries listed
- 1
- Registry update
- June 4, 2013
CompletedNCT01831947
Efficacy Study of Ranibizumab on Patients With Age-related Macular Degeneration.
PHASE4 · 40 planned enrolment
- Countries listed
- 1
- Registry update
- April 15, 2013
CompletedNCT00891735
A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)
PHASE3 · 1,097 planned enrolment
- Countries listed
- 1
- Registry update
- January 18, 2013
CompletedNCT00509795
Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)
PHASE3 · 1,217 planned enrolment
- Countries listed
- 2
- Registry update
- December 28, 2012
CompletedNCT00793923
A Prospective Study Comparing Ranibizumab Plus Dexamethasone Combination Therapy Versus Ranibizumab Monotherapy for Wet AMD
PHASE1 · PHASE2 · 40 planned enrolment
- Countries listed
- 1
- Registry update
- December 19, 2012
TerminatedNCT01122511
Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration
PHASE2 · 4 planned enrolment
- Countries listed
- 1
- Registry update
- September 5, 2012
CompletedNCT00775411
Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)
PHASE2 · 44 planned enrolment
- Countries listed
- 3
- Registry update
- September 3, 2012
UnknownNCT01676506
Genetic Polymorphisms in Ranibizumab Treatment in Wet Age-Related Macular Degeneration (AMD)
Phase not reported · 300 planned enrolment
- Countries listed
- 1
- Registry update
- August 31, 2012
WithdrawnNCT00726973
Pilot Study Reduced Fluence PDT /Visudyne With Ranibizumab vs Ranibizumab Monotherapy for Exudative Age-related Macular Degeneration (AMD)
Phase not reported · 0 planned enrolment
- Countries listed
- 0
- Registry update
- May 10, 2012
CompletedNCT00590694
Lucentis for Age-related Macular Degeneration Pigment Epithelial Detachments
PHASE2 · PHASE3 · 15 planned enrolment
- Countries listed
- 1
- Registry update
- April 12, 2012
CompletedNCT00680498
Combination Lucentis and Ocular Photodynamic Therapy With Visudyne, With Evaluation-based Retreatment
PHASE4 · 10 planned enrolment
- Countries listed
- 1
- Registry update
- March 28, 2012
CompletedNCT00599222
The Ranibizumab Plus Transpupillary Thermotherapy for Neovascular Age-Related Macular Degeneration (AMD) Study
PHASE3 · 100 planned enrolment
- Countries listed
- 1
- Registry update
- November 22, 2011
TerminatedNCT00857259
The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular Degeneration
PHASE2 · 16 planned enrolment
- Countries listed
- 2
- Registry update
- August 19, 2011
UnknownNCT00454389
A Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular Degeneration
PHASE3 · 494 planned enrolment
- Countries listed
- 9
- Registry update
- July 27, 2011
TerminatedNCT00433017
Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
PHASE2 · PHASE3 · 255 planned enrolment
- Countries listed
- 12
- Registry update
- April 21, 2011
CompletedNCT00539734
Changes in Retinal Function After Intravitreal Ranibizumab for Age-related Macular Degeneration
Phase not reported · 25 planned enrolment
- Countries listed
- 1
- Registry update
- April 15, 2011
CompletedNCT00284089
Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration
PHASE1 · PHASE2 · 88 planned enrolment
- Countries listed
- 1
- Registry update
- February 24, 2011
CompletedNCT00331864
SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
PHASE3 · 531 planned enrolment
- Countries listed
- 1
- Registry update
- February 18, 2011
UnknownNCT01249937
Sub-tenon Triamcinolone Acetonide in Age-Related Macular Degeneration as Adjunct to Ranibizumab
PHASE2 · 30 planned enrolment
- Countries listed
- 1
- Registry update
- February 9, 2011
CompletedNCT00390208
Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration
PHASE2 · 60 planned enrolment
- Countries listed
- 1
- Registry update
- May 27, 2010
CompletedNCT00395551
Safety Study of Ranibizumab Eye Injections to Treat Choroidal Neovascularization That Was Caused Other Than by Age-Related Macular Degeneration.
PHASE1 · 30 planned enrolment
- Countries listed
- 0
- Registry update
- January 8, 2010
UnknownNCT00559715
Prevention of Vision Loss in Patients With Age-Related Macular Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab
PHASE3 · 366 planned enrolment
- Countries listed
- 1
- Registry update
- March 26, 2009
UnknownNCT00813891
Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration
PHASE4 · 180 planned enrolment
- Countries listed
- 1
- Registry update
- December 23, 2008
CompletedNCT00288561
Study of Ranibizumab Administered in Conjunction With Photodynamic Therapy With Verteporfin in Patients With Subfoveal Choroidal Neovascularization and Age-Related Macular Degeneration
PHASE2 · planned enrolment not reported
- Countries listed
- 1
- Registry update
- June 19, 2008